EPA, FDA Agreements Aim To Clear Up Burdensome Regulatory Environment
This article was originally published in The Gray Sheet
Executive Summary
Complex, overlapping federal regulations potentially are blocking availability of innovative disinfectants for medical uses, speakers at a recent Food & Drug Law Institute meeting suggested
You may also be interested in...
Multi-Agency Nanotech Toxicity Initiative Funded At $105.9 Mil. In FY 2004
FDA will continue to monitor potential safety threats associated with some nanotechnology drug delivery devices, according to FDA Associate Commissioner for Science Norris Alderson, PhD
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.